A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
Clinical trial NCT02828930 · COMPLETED
Trial details
- NCT number
- NCT02828930
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-08
- Primary completion
- 2017-06-19
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.